MPO and chronic obstructive pulmonary disease: Using a guinea pig model of COPD, Churg and colleagues showed that inhibition of MPO with a small molecule can halt the progression of smoke-induced pathologic and physiological changes of COPD including emphysema, small airway remodeling and pulmonary arterial remodeling even when the drug was provided 3 months following smoking initiation [11].